Latin America Phentermine Hydrochloride Market Size, Share & Trends Analysis Report By Dosage Form (Tablets, Capsules, Orally Disintegrating Tablets (ODT), Extended-Release Formulations), By Strength (8 mg, 15 mg, 18.75 mg, 30 mg), By Country (UAE, Turkey, Saudi Arabia, South Africa, Egypt, Nigeria) and Forecast, 2026-2034

Latin Phentermine Hydrochloride Market Trends

Digital Weight-Management Models Reshape Prescription Access

Telehealth, electronic prescribing, digital consultations, and remotely monitored weight-management programs are changing pharmaceutical access patterns. With 67.5% of adults and 37.6% of people aged 5–19 in the Americas classified as overweight or obese, digital channels potentially address patient populations numbering in the tens of millions.

Latin America Phentermine Hydrochloride Market Drivers

High Obesity Burden Expands the Treatable Patient Pool

Obesity prevalence remains a fundamental demand catalyst. Mexico's Ministry of Health reported that 38.9% of adults have obesity and another 37.3% are overweight, while obesity prevalence reaches 40.2% in rural locations versus 38.6% in urban areas. Brazil data indicate 68% of the population has excess weight, including 31% with obesity and 37% with overweight. These rates create a substantial physician-addressable population for diet, exercise, behavioral interventions, and appropriate prescription therapies.

Latin America Phentermine Hydrochloride Market Opportunities

Telehealth and Generic Access Broaden Commercial Reach

Digital consultations and generic-drug availability can improve access among large populations requiring medically supervised weight management. Mexico alone reports 38.9% adult obesity and 37.3% overweight prevalence, while Brazil reports 68% excess-weight prevalence. Even modest conversion of these populations into appropriately screened pharmacotherapy pathways could support substantial prescription volumes, particularly through retail, specialty-clinic, and digitally enabled pharmacy networks.

Latin Phentermine Hydrochloride Market Segmentation

The industry is segmented by dosage form, strength, route of administration, distribution channel, application, end user, and sales type. Among dosage forms, tablets represent approximately 48.1% of 2026 value, while capsules represent approximately 25.8%, ODTs 15.0%, and extended-release formulations 11.1%.

By Dosage Form

Tablets are the largest supplied dosage-form segment, increasing from USD 21.93 million in 2025 to USD 23.45 million in 2026 and USD 40.15 million in 2034 at a 6.95% CAGR. Their established prescribing familiarity and conventional manufacturing economics support their leading position.

Capsules are the fastest-growing supplied format at a 7.10% CAGR, moving from USD 12.55 million in 2026 to USD 21.73 million by 2034. ODTs reach USD 12.50 million at a 6.93% CAGR, while extended-release formulations reach USD 9.19 million at a 6.83% CAGR.

By Strength

The market covers 8 mg, 15 mg, 18.75 mg, 30 mg, and 37.5 mg formulations. Strength selection depends on prescribing practices, treatment response, tolerability, and patient-specific clinical assessment.

Higher-dose and lower-dose products coexist within individualized obesity-management pathways. No strength-level monetary value or CAGR was supplied; therefore, numerical strength-level estimates are not substituted for the mandatory dataset.

By Route of Administration

Oral and sublingual delivery constitute the specified routes. Conventional oral administration benefits from established tablet and capsule availability, while alternative delivery formats address differentiated patient requirements.

The supplied data assign USD 23.45 million to tablets and USD 12.55 million to capsules in 2026, demonstrating the commercial importance of conventional solid formulations; route-specific CAGR figures were not provided.

By Distribution Channel

Hospital pharmacies, retail pharmacies, online pharmacies, and weight-loss clinics form the distribution structure. Prescription controls make clinician and pharmacy participation central to product access.

The total dosage-form value rises from USD 48.73 million in 2026 to USD 83.57 million in 2034 at 6.95%; however, channel-specific values and CAGRs were not supplied and are therefore not inferred.

By Application

Applications comprise obesity with BMI ≥30 and overweight with comorbidities at BMI ≥27. These groups represent clinically differentiated populations requiring medical assessment before pharmacotherapy.

The regional need is substantial: 67.5% of adults across the Americas are overweight or obese, while Mexico reports 38.9% adult obesity and 37.3% overweight prevalence. End-user-specific revenue and CAGR figures were not supplied.

By Sales Type

Branded and generic drugs form the sales-type segmentation. Generic competition supports affordability, while branded positioning can depend on formulation differentiation and distribution strategy.

Across all supplied dosage forms, value expands from USD 45.56 million in 2025 to USD 83.57 million in 2034 at 6.95%. Separate branded and generic CAGRs were not supplied.

Latin America Phentermine Hydrochloride Market Country Outlook

The requested regional list of UAE, Turkey, Saudi Arabia, South Africa, Egypt, and Nigeria is outside Latin America and cannot be reconciled with the mandatory Latin America dataset. Accordingly, the supplied Latin America countries are reported without fabricating geographic contributions.

Brazil

Brazil leads at USD 18.69 million in 2026, approximately 38.4% of the USD 48.71 million country total. It reaches USD 31.66 million by 2034 at a 6.81% CAGR. WHO reports adult obesity prevalence of 28.1%, reinforcing a substantial addressable obesity-management population.

Mexico

Mexico contributes approximately 29.1% in 2026 with USD 14.19 million and reaches USD 24.61 million in 2034 at the fastest country CAGR of 7.12%. National authorities report 38.9% adult obesity and 37.3% overweight prevalence.

Colombia

Colombia represents approximately 8.0% of 2026 country value at USD 3.89 million and is forecast to reach USD 6.66 million by 2034, registering a 6.94% CAGR.

Chile

Chile contributes approximately 7.5% in 2026 at USD 3.66 million. Value is projected at USD 6.18 million in 2034, representing a 6.77% CAGR.

Top players in Latin America Phentermine Hydrochloride Market

• Teva Pharmaceutical Industries Ltd.
• KVK-Tech, Inc.
• Lannett Company, Inc.
• Sandoz
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma
• Amneal Pharmaceuticals
• Hikma Pharmaceuticals
• Lupin Limited
• Alvogen
• Elite Pharmaceuticals
• Currax Pharmaceuticals

Top Two Companies

• Teva Pharmaceutical Industries Ltd.

Teva maintains broad generic-drug manufacturing and distribution capabilities that support competitive positioning in prescription pharmaceuticals. A verified Latin America phentermine-specific company percentage was not supplied; therefore, no unsupported company share is assigned. Competitive positioning depends on generic economics, pharmacy availability, manufacturing scale, and regulatory compliance across a regional opportunity valued at approximately USD 48.7 million in 2026.

• KVK-Tech, Inc.

KVK-Tech is associated with generic prescription pharmaceutical manufacturing, including phentermine products. Its positioning is supported by specialization in established generic therapies and conventional dosage forms. No verified Latin America-specific percentage was provided, so a company share cannot responsibly be stated. The relevant competitive environment includes tablets representing approximately 48.1% and capsules approximately 25.8% of supplied 2026 dosage-form value.

Recent Developments in Latin America Phentermine Hydrochloride Market

• 2026: The FDA issued warning letters to 30 telehealth companies concerning misleading promotion of compounded GLP-1 medicines, reinforcing compliance expectations across digital weight-management channels.
• 2025: PAHO reported that nine countries were intensifying obesity-control actions, with 67.5% of adults in the Americas classified as overweight or obese.
• 2025: Brazil data cited by Agência Brasil indicated 68% excess-weight prevalence, comprising 31% obesity and 37% overweight.
• 2025: Mexico implemented stronger school nutrition controls as part of its response to elevated obesity and diabetes prevalence, adding preventive-policy pressure alongside pharmaceutical treatment pathways.

Research Methodology

The analysis uses 2025 as the base year, 2026 as the current year, 2022–2024 as the historical period, and 2026–2034 as the forecast horizon. Mandatory monetary forecasts supplied with the request were treated as the primary quantitative source and were not replaced by external estimates. Percentage contributions were calculated directly from supplied totals; for example, Brazil's USD 18.69 million represents approximately 38.4% of the USD 48.71 million 2026 country total, while tablets' USD 23.45 million represent approximately 48.1% of the USD 48.73 million dosage-form total. External WHO, PAHO, government, and regulatory information was used only for contextual epidemiological, policy, and industry analysis. Where segment, company, production-volume, or geographic data were not supplied or reliably evidenced, figures were explicitly left unstated rather than fabricated.